Published on 8 Sep 2022 on Zacks via Yahoo Finance
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its targeted injectable implant candidate — iDose TR — in glaucoma patients. Data from the studies showed that the slow-release iDose TR achieved excellent tolerability and a favorable safety profile. The candidate achieved non-inferior reductions in intraocular pressure (IOP) in three months from baseline compared to the timolol ophthalmic solution.
Price Performance
Shares of Glaukos rallied 18.5% on Sep 7, following the data readout. Shares of the company have gained 28.2% so far this year against the industry’s 32.4% fall and the S&P 500's 18.7% decline.